What: Hera Biotech company said they got good interim results from clinical trials of their endometriosis diagnostic tool. In the first 38 patients tested, the diagnostic test, which looks at swabbed endometrial cells, has an accuracy rate of 94%.
Why it matters: More data is needed, but Hera CEO said the result “suggests that Hera’s molecular diagnostic test has the potential to replace surgical diagnosis and greatly improve the woefully inadequate state of endometriosis diagnosis and treatment that exists today.”
Source: Hera Biotech via BusinessWire